Patients with advanced liver disease have a hemostatic profile that typically includes thrombocytopenia and reduced coagulation factors; however, these alterations are counteracted by fibrinolysis inhibition, decreased protein C, and increased endothelial-derived von Willebrand factor (vWF) and factor VIII (FVIII). This evidence concerns the gene VWF and liver disorder.